Fusion Antibodies Plc (GB:FAB) has released an update.
Fusion Antibodies plc, a specialist in pre-clinical antibody discovery and engineering, reports significant financial progress in the first half of the fiscal year 2025, with unaudited revenues roughly doubling to £1.2m and a positive shift in gross margin to 29%. The company has expanded its collaboration with the National Cancer Institute and secured new contracts, bolstering its position in the antibody therapeutics market. They are also maintaining a careful cash control strategy with a runway extending into the second half of FY26 without plans for an equity cash raise.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.
